Conjugated Monoclonal Antibodies Market Report 2025

This Conjugated Monoclonal Antibodies market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The conjugated monoclonal antibodies market size has grown strongly in recent years. It will grow from $10.9 billion in 2024 to $11.48 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to the increasing prevalence of cancer, expansion of the private healthcare sector, government support, and growing patient population.

The conjugated monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $14.64 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increased access to healthcare, growing demand for minimally invasive procedures, immunotherapeutic combinations, expanding healthcare access, and expanding indications. Major trends in the forecast period include advances in drug delivery, biomarker-driven development, next-generation conjugates, and patient-centric care.

The rising popularity and therapeutic potential of conjugated monoclonal antibodies, specifically antibody-drug conjugates (ADCs), are projected to fuel demand within the market. ADCs, comprising monoclonal antibodies coupled with potent cytotoxic drugs through linkers to target antigen-expressing tumor cells, are primarily employed in cancer treatment. Despite the U.S. Food and Drug Administration approving only three ADCs in the past few years, the correlation between increased approvals and the application of conjugated monoclonal antibodies, particularly in cancer treatment, substantiates the market's growth trajectory.

The significant prevalence of cancer is anticipated to drive the growth of the conjugated monoclonal antibodies market in the future. Cancer encompasses a range of diseases characterized by the uncontrolled proliferation and dissemination of abnormal cells within the body, which can lead to the formation of tumors or masses. Conjugated monoclonal antibodies are mainly utilized in cancer treatment due to their targeted and precise action, which enhances the overall quality of life for patients. For example, a report from the American Cancer Society in September 2024 indicated that by 2050, the number of cancer cases in men worldwide is expected to surge by 84%, rising from 10.3 million in 2022 to 19 million, while cancer-related deaths are projected to increase by 93%, from 5.4 million in 2022 to 10.5 million. Consequently, the high incidence of cancer is fueling the growth of the conjugated monoclonal antibodies market.

Leading firms operating in the realm of conjugated monoclonal antibodies are leveraging strategic partnerships to bolster their capabilities and offer comprehensive solutions. These partnerships entail companies leveraging each other's strengths and resources for mutual success. For example, in July 2023, BeiGene Ltd., a U.S.-based biotech firm, joined forces with Duality Biologics, a China-based clinical stage company, aiming to develop and commercialize a preclinical antibody-drug conjugate (ADC) therapy targeting specific solid tumors. The combined strengths of both entities are poised to expedite the development and market entry of this promising ADC therapy.

In June 2023 was indeed aimed at bolstering Lonza's capabilities in the development and manufacturing of antibody-drug conjugates (ADCs). The acquisition was focused on enhancing Lonza's ADC portfolio and gaining access to Synaffix's pipeline of ADC candidates. The specific financial details of the acquisition were not disclosed.

Major companies operating in the conjugated monoclonal antibodies market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., Spectrum Pharmaceuticals Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, Amgen, Celgene, Emergent BioSolutions, Genzyme, Incyte Corporation, Kite Pharma, MorphoSys AG, Regeneron Pharmaceuticals, Seattle Genetics.

Conjugated monoclonal antibodies refer to compounds resulting from chemically binding a medication to a monoclonal antibody. These antibodies specifically target proteins or receptors on particular cell types, such as cancer cells, allowing the associated medication to enter these cells, eliminate them, and spare healthy cells.

The primary drugs categorized as conjugated monoclonal antibodies are Adcetris and Kadcyla. Adcetris, a brand-name medication, is designed to treat specific forms of lymphoma in adults. Lymphoma is a type of cancer affecting the lymphatic system and lymphocytes, a type of white blood cell. These therapies utilize various technologies, including cleavable and non-cleavable linkers, and find application in treating conditions such as blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and other malignancies.

The conjugated monoclonal antibodies market research report is one of a series of new reports that provides conjugated monoclonal antibodies market statistics, including industry global market size, regional shares, competitors with a conjugated monoclonal antibodies market share, detailed conjugated monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the conjugated monoclonal antibodies industry. The conjugated monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

North America was the largest region in the conjugated monoclonal antibody market in 2024. The Middle East is expected to be the fastest growing region in the global conjugated monoclonal antibodies market share during the forecast period. The regions covered in the conjugated monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the conjugated monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The conjugated monoclonal antibodies market consists of sales of Brentuximab vedotin and Ado-trastuzumab emtansine. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.